Skip to content

Pipeline

Aramis Biosciences was founded to revolutionize the standard of care in ocular immunology, beginning with Dry Eye Disease.

Candidate Indication
Preclinical IND Phase 1 Phase 2 Phase 3
Dry Eye Disease
A197
Other Immuno‑Inflammatory Ocular Disease